Developed the first genomic test for personalized HER2+ breast cancer treatments
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
The new test, called HER2DX, analyzes RNA on 27 genes to predict survival outcomes and the likelihood that patients will respond to treatment.
A study conducted at Hospital Clínic analysed the genetic profile of more than 300 patients with solid tumours using a liquid biopsy blood test, re...
The Hospital Clínic-IDIBAPS has developed the first CAR T-cell therapy in Europe to treat multiple myeloma, the second most common type of blood ca...
On Thursday, 11 November, the Spanish Cancer Association (AECC) awarded the AECC 2021 Grants for Cancer Research at an event held at the organizati...
The Hospital Clínic Medical Oncology Service, led by Dr. Aleix Prat, has launched a home infusion programme for solid organ cancer patients and imm...
Cardiology, cardiac surgery, orthopaedic surgery and traumatology, gastroenterology, endocrinology and nutrition, neurology and medical oncology ar...
The ACROPOLI clinical trial is being launched. It is a pioneering, nationwide research study that aims to assess the efficacy of immunotherapy in 2...
In a study published in the Journal of Clinical Oncology, researchers from the Hospital Clínic-IDIBAPS-UB and SOLTI showed the predictive capacity...
Dr. Aleix Prat, head of the Service of Medical Oncology at Hospital Clínic, head of the Translational genomics and targeted therapies in solid tumo...
The University of Barcelona, Hospital Clínic and the pharmaceutical company AstraZeneca created the UB-Hospital Clínic Chair on Lung Cancer AstraZe...